The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study.
Aged
Alkaline Phosphatase
/ genetics
Anti-Ulcer Agents
/ administration & dosage
Aspartate Aminotransferases
/ genetics
Bacillus
/ classification
Clostridiales
/ classification
Dysbiosis
/ chemically induced
Esomeprazole
/ administration & dosage
Female
Gastroesophageal Reflux
/ microbiology
Gastrointestinal Microbiome
/ physiology
Gene Expression Regulation
Haptoglobins
/ genetics
Humans
Lactobacillus
/ classification
Lactococcus
/ classification
Leukocyte L1 Antigen Complex
/ genetics
Male
Middle Aged
Pantoprazole
/ administration & dosage
Peptic Ulcer
/ microbiology
Pilot Projects
Prebiotics
/ administration & dosage
Probiotics
/ therapeutic use
Protein Precursors
/ genetics
Proton Pump Inhibitors
/ administration & dosage
Quality of Life
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 02 2020
17 02 2020
Historique:
received:
28
05
2019
accepted:
30
01
2020
entrez:
19
2
2020
pubmed:
19
2
2020
medline:
18
11
2020
Statut:
epublish
Résumé
Side effects of proton pump inhibitors (PPI) can be linked to the changes in the intestinal microbiome that occur during therapy, especially in long-term users. Therefore, the microbiome might also be a key player in the reduction of PPI side effects. We tested the effects of a three-month intervention with a multispecies synbiotic on intestinal inflammation, gut barrier function, microbiome composition, routine laboratory parameters and quality of life in patients with long-term PPI therapy. Thirty-six patients received a daily dose of a multispecies synbiotic for three months and were clinically observed without intervention for another three months. After intervention 17% of patients reached normal calprotectin levels; the overall reduction did not reach statistical significance (-18.8 ng/mg; 95%CI: -50.5; 12.9, p = 0.2). Elevated zonulin levels could be significantly reduced (-46.3 ng/mg; 95%CI: -71.4; -21.2; p < 0.001). The abundance of Stomatobaculum in the microbiome was reduced and Bacillus increased during the intervention. Furthermore, albumin, alkaline phosphatase and thrombocyte count were significantly increased and aspartate transaminase was significantly decreased during intervention. Gastrointestinal quality of life showed significant improvements. In conclusion, microbiome-related side effects of long-term PPI use can be substantially reduced by synbiotic intervention. Further studies are warranted to optimize dosage and duration of the intervention.
Identifiants
pubmed: 32066847
doi: 10.1038/s41598-020-59550-x
pii: 10.1038/s41598-020-59550-x
pmc: PMC7026433
doi:
Substances chimiques
Anti-Ulcer Agents
0
Haptoglobins
0
Leukocyte L1 Antigen Complex
0
Prebiotics
0
Protein Precursors
0
Proton Pump Inhibitors
0
zonulin
0
Pantoprazole
D8TST4O562
Aspartate Aminotransferases
EC 2.6.1.1
Alkaline Phosphatase
EC 3.1.3.1
Esomeprazole
N3PA6559FT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2723Références
Freedberg, D. E., Kim, L. S. & Yang, Y. X. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology 152, 706–715, https://doi.org/10.1053/j.gastro.2017.01.031 (2017).
doi: 10.1053/j.gastro.2017.01.031
pubmed: 28257716
Eriksson, S., Langstrom, G., Rikner, L., Carlsson, R. & Naesdal, J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. European journal of gastroenterology & hepatology 7, 467–475 (1995).
Malfertheiner, P., Kandulski, A. & Venerito, M. Proton-pump inhibitors: understanding the complications and risks. Nature reviews. Gastroenterology & hepatology 14, 697–710, https://doi.org/10.1038/nrgastro.2017.117 (2017).
doi: 10.1038/nrgastro.2017.117
Janarthanan, S., Ditah, I., Adler, D. G. & Ehrinpreis, M. N. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. The American journal of gastroenterology 107, 1001–1010, https://doi.org/10.1038/ajg.2012.179 (2012).
doi: 10.1038/ajg.2012.179
pubmed: 22710578
Leonard, J., Marshall, J. K. & Moayyedi, P. Systematic review of the risk of enteric infection in patients taking acid suppression. The American journal of gastroenterology 102, 2047–2056, quiz 2057, https://doi.org/10.1111/j.1572-0241.2007.01275.x (2007).
doi: 10.1111/j.1572-0241.2007.01275.x
Bavishi, C. & Dupont, H. L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Alimentary pharmacology & therapeutics 34, 1269–1281, https://doi.org/10.1111/j.1365-2036.2011.04874.x (2011).
doi: 10.1111/j.1365-2036.2011.04874.x
Compare, D. et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. European journal of clinical investigation 41, 380–386, https://doi.org/10.1111/j.1365-2362.2010.02419.x (2011).
doi: 10.1111/j.1365-2362.2010.02419.x
pubmed: 21128930
Schmulson, M. J. & Frati-Munari, A. C. Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. Revista de gastroenterologia de Mexico 84, 44–51, https://doi.org/10.1016/j.rgmx.2018.02.008 (2019).
doi: 10.1016/j.rgmx.2018.02.008
pubmed: 29678362
Marcuard, S. P., Albernaz, L. & Khazanie, P. G. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Annals of internal medicine 120, 211–215 (1994).
doi: 10.7326/0003-4819-120-3-199402010-00006
Heidelbaugh, J. J. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Therapeutic advances in drug safety 4, 125–133, https://doi.org/10.1177/2042098613482484 (2013).
doi: 10.1177/2042098613482484
pubmed: 25083257
pmcid: 4110863
Cohen, M. Proton pump inhibitors may cause elevation in faecal calprotectin levels. The British journal of general practice: the journal of the Royal College of General Practitioners 66, 350, https://doi.org/10.3399/bjgp16X685813 (2016).
doi: 10.3399/bjgp16X685813
Poullis, A., Foster, R., Mendall, M. A., Shreeve, D. & Wiener, K. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. European journal of gastroenterology & hepatology 15, 573–574, author reply 574 (2003).
Seto, C. T., Jeraldo, P., Orenstein, R., Chia, N. & DiBaise, J. K. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2, 42, https://doi.org/10.1186/2049-2618-2-42 (2014).
doi: 10.1186/2049-2618-2-42
pubmed: 25426290
pmcid: 4242847
Su, T., Lai, S., Lee, A., He, X. & Chen, S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. Journal of gastroenterology 53, 27–36, https://doi.org/10.1007/s00535-017-1371-9 (2018).
doi: 10.1007/s00535-017-1371-9
pubmed: 28770351
Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740–748, https://doi.org/10.1136/gutjnl-2015-310376 (2016).
doi: 10.1136/gutjnl-2015-310376
pubmed: 26657899
Clooney, A. G. et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Alimentary pharmacology & therapeutics 43, 974–984, https://doi.org/10.1111/apt.13568 (2016).
doi: 10.1111/apt.13568
Bajaj, J. S. et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 307, G951–957, https://doi.org/10.1152/ajpgi.00268.2014 (2014).
doi: 10.1152/ajpgi.00268.2014
pubmed: 25258407
pmcid: 4233285
Tsuda, A. et al. Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract. Clinical and translational gastroenterology 6, e89, https://doi.org/10.1038/ctg.2015.20 (2015).
doi: 10.1038/ctg.2015.20
pubmed: 26065717
pmcid: 4816248
Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65, 749–756, https://doi.org/10.1136/gutjnl-2015-310861 (2016).
doi: 10.1136/gutjnl-2015-310861
pubmed: 26719299
He, X., McLean, J. S., Guo, L., Lux, R. & Shi, W. The social structure of microbial community involved in colonization resistance. The ISME Journal 8, 564–574, https://doi.org/10.1038/ismej.2013.172 (2014).
doi: 10.1038/ismej.2013.172
pubmed: 24088624
Case, T. J. Invasion resistance arises in strongly interacting species-rich model competition communities. Proceedings of the National Academy of Sciences of the United States of America 87, 9610–9614 (1990).
doi: 10.1073/pnas.87.24.9610
Freedberg, D. E. et al. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. Gastroenterology 149, 883–885.e889, https://doi.org/10.1053/j.gastro.2015.06.043 (2015).
doi: 10.1053/j.gastro.2015.06.043
pubmed: 26164495
pmcid: 4584196
Sieczkowska, A., Landowski, P., Zagozdzon, P., Kaminska, B. & Lifschitz, C. Small Bowel Bacterial Overgrowth Associated with Persistence of Abdominal Symptoms in Children Treated with a Proton Pump Inhibitor. The Journal of pediatrics 166, 1310–1312 e1311, https://doi.org/10.1016/j.jpeds.2015.01.004 (2015).
doi: 10.1016/j.jpeds.2015.01.004
pubmed: 25681195
Belei, O., Olariu, L., Dobrescu, A., Marcovici, T. & Marginean, O. Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux? Journal of neurogastroenterology and motility 24, 51–57, https://doi.org/10.5056/jnm17059 (2018).
doi: 10.5056/jnm17059
pubmed: 29291607
pmcid: 5753903
Johansson, M. L. et al. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Applied and environmental microbiology 59, 15–20 (1993).
doi: 10.1128/AEM.59.1.15-20.1993
Lidbeck, A., Gustafsson, J. A. & Nord, C. E. Impact of Lactobacillus acidophilus supplements on the human oropharyngeal and intestinal microflora. Scandinavian journal of infectious diseases 19, 531–537 (1987).
doi: 10.3109/00365548709032419
Blaabjerg, S., Artzi, D. M. & Aabenhus, R. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. Antibiotics (Basel, Switzerland) 6, https://doi.org/10.3390/antibiotics6040021 (2017).
doi: 10.3390/antibiotics6040021
Pattani, R., Palda, V. A., Hwang, S. W. & Shah, P. S. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open medicine: a peer-reviewed, independent, open-access journal 7, e56–67 (2013).
Didari, T., Mozaffari, S., Nikfar, S. & Abdollahi, M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World journal of gastroenterology 21, 3072–3084, https://doi.org/10.3748/wjg.v21.i10.3072 (2015).
doi: 10.3748/wjg.v21.i10.3072
pubmed: 25780308
pmcid: 4356930
Lamprecht, M. et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. Journal of the International Society of Sports Nutrition 9, 45, https://doi.org/10.1186/1550-2783-9-45 (2012).
doi: 10.1186/1550-2783-9-45
pubmed: 22992437
pmcid: 3465223
Fukui, H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World journal of hepatology 7, 425–442, https://doi.org/10.4254/wjh.v7.i3.425 (2015).
doi: 10.4254/wjh.v7.i3.425
pubmed: 25848468
pmcid: 4381167
Liu, Q. et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39, 1441–1449, https://doi.org/10.1002/hep.20194 (2004).
doi: 10.1002/hep.20194
pubmed: 15122774
Lata, J. et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. European journal of gastroenterology & hepatology 19, 1111–1113, https://doi.org/10.1097/MEG.0b013e3282efa40e (2007).
doi: 10.1097/MEG.0b013e3282efa40e
Dhiman, R. K. et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 147, 1327–1337.e1323, https://doi.org/10.1053/j.gastro.2014.08.031 (2014).
doi: 10.1053/j.gastro.2014.08.031
pubmed: 25450083
Kirpich, I. A. et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol (Fayetteville, N.Y.) 42, 675–682, https://doi.org/10.1016/j.alcohol.2008.08.006 (2008).
doi: 10.1016/j.alcohol.2008.08.006
pmcid: 2630703
Krumbeck, J. A., Maldonado-Gomez, M. X., Ramer-Tait, A. E. & Hutkins, R. W. Prebiotics and synbiotics: dietary strategies for improving gut health. Current opinion in gastroenterology 32, 110–119, https://doi.org/10.1097/mog.0000000000000249 (2016).
doi: 10.1097/mog.0000000000000249
pubmed: 26825589
Horvath, A. et al. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. Scientific reports 9, 12000, https://doi.org/10.1038/s41598-019-48352-5 (2019).
doi: 10.1038/s41598-019-48352-5
pubmed: 31427714
pmcid: 6700098
Liu, Z. et al. Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after colorectal liver metastases surgery: a double-center and double-blind randomized clinical trial. BMC gastroenterology 15, 34, https://doi.org/10.1186/s12876-015-0260-z (2015).
doi: 10.1186/s12876-015-0260-z
pubmed: 25881090
pmcid: 4374379
Liu, Z. H. et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. The American journal of clinical nutrition 97, 117–126, https://doi.org/10.3945/ajcn.112.040949 (2013).
doi: 10.3945/ajcn.112.040949
pubmed: 23235200
Horvath, A. et al. Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. Alimentary pharmacology & therapeutics, https://doi.org/10.1111/apt.13788 (2016).
doi: 10.1111/apt.13788
Sizova, M. V. et al. Stomatobaculum longum gen. nov., sp. nov., an obligately anaerobic bacterium from the human oral cavity. International journal of systematic and evolutionary microbiology 63, 1450–1456, https://doi.org/10.1099/ijs.0.042812-0 (2013).
doi: 10.1099/ijs.0.042812-0
pubmed: 22843721
pmcid: 3709536
Horvath, A. et al. Changes in the intestinal microbiome during probiotic intervention in cirrhosis. Journal of Hepatology 70, e625–e854 (2019).
doi: 10.1016/S0618-8278(19)31290-3
Sanders, M. E. Probiotics: definition, sources, selection, and uses. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 46 Suppl 2, S58–61; discussion S144–151, https://doi.org/10.1086/523341 (2008).
doi: 10.1086/523341
Whorwell, P. J. et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. The American journal of gastroenterology 101, 1581–1590, https://doi.org/10.1111/j.1572-0241.2006.00734.x (2006).
doi: 10.1111/j.1572-0241.2006.00734.x
pubmed: 16863564
Szulinska, M., Loniewski, I., van Hemert, S. & Sobieska, M. Dose-Dependent Effects of Multispecies Probiotic Supplementation on the Lipopolysaccharide (LPS) Level and Cardiometabolic Profile in Obese Postmenopausal Women: A 12-Week Randomized Clinical Trial. 10, https://doi.org/10.3390/nu10060773 (2018).
doi: 10.3390/nu10060773
Venturi, A. et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Alimentary pharmacology & therapeutics 13, 1103–1108 (1999).
doi: 10.1046/j.1365-2036.1999.00560.x
Ma, Y. Y. et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World journal of gastroenterology 19, 6911–6918, https://doi.org/10.3748/wjg.v19.i40.6911 (2013).
doi: 10.3748/wjg.v19.i40.6911
pubmed: 24187469
pmcid: 3812493
A., S. L., D., V. R., Manohar, T. & A., A. L. Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. Euroasian journal of hepato-gastroenterology 7, 130–137, https://doi.org/10.5005/jp-journals-10018-1233 (2017).
doi: 10.5005/jp-journals-10018-1233
Khalesi, S. et al. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. European journal of nutrition 57, 2037–2053, https://doi.org/10.1007/s00394-017-1568-y (2018).
doi: 10.1007/s00394-017-1568-y
pubmed: 29119235
Le, D. M. H. & Millan, J. L. Structural evidence of functional divergence in human alkaline phosphatases. The Journal of biological chemistry 277, 49808–49814, https://doi.org/10.1074/jbc.M207394200 (2002).
doi: 10.1074/jbc.M207394200
Regidor, D. L. et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. Journal of the American Society of Nephrology: JASN 19, 2193–2203, https://doi.org/10.1681/asn.2008010014 (2008).
doi: 10.1681/asn.2008010014
pubmed: 18667733
Gleissenthall, G. V. et al. Tryptophan metabolism in post-withdrawal alcohol-dependent patients. Alcohol and alcoholism 49, 251–255, https://doi.org/10.1093/alcalc/agu011 (2014).
doi: 10.1093/alcalc/agu011
pubmed: 24644258
Riggle, K. M. et al. Intestinal alkaline phosphatase prevents the systemic inflammatory response associated with necrotizing enterocolitis. The Journal of surgical research 180, 21–26, https://doi.org/10.1016/j.jss.2012.10.042 (2013).
doi: 10.1016/j.jss.2012.10.042
pubmed: 23158403
Rentea, R. M. et al. Intestinal alkaline phosphatase administration in newborns is protective of gut barrier function in a neonatal necrotizing enterocolitis rat model. Journal of pediatric surgery 47, 1135–1142, https://doi.org/10.1016/j.jpedsurg.2012.03.018 (2012).
doi: 10.1016/j.jpedsurg.2012.03.018
pubmed: 22703783
Liu, W. et al. Intestinal Alkaline Phosphatase Regulates Tight Junction Protein Levels. Journal of the American College of Surgeons 222, 1009–1017, https://doi.org/10.1016/j.jamcollsurg.2015.12.006 (2016).
doi: 10.1016/j.jamcollsurg.2015.12.006
pubmed: 27106638
Peters, E., Masereeuw, R. & Pickkers, P. The potential of alkaline phosphatase as a treatment for sepsis-associated acute kidney injury. Nephron. Clinical practice 127, 144–148, https://doi.org/10.1159/000363256 (2014).
doi: 10.1159/000363256
pubmed: 25343839
Pickkers, P. et al. Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial. Jama 320, 1998–2009, https://doi.org/10.1001/jama.2018.14283 (2018).
doi: 10.1001/jama.2018.14283
pubmed: 30357272
pmcid: 6248164
Hemert, S. O. G. Influence of the Multispecies Probiotic Ecologic® BARRIER on Parameters of Intestinal Barrier Function. Food and Nutrition Sciences, 1739–1745, https://doi.org/10.4236/fns.2014.518187 (2014).
doi: 10.4236/fns.2014.518187
Shukla, S., Shukla, A., Mehboob, S. & Guha, S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Alimentary pharmacology & therapeutics 33, 662–671, https://doi.org/10.1111/j.1365-2036.2010.04574.x (2011).
doi: 10.1111/j.1365-2036.2010.04574.x
Stadlbauer, V. et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J. Hepatol 48, 945–951, https://doi.org/10.1016/j.jhep.2008.02.015 (2008).
doi: 10.1016/j.jhep.2008.02.015
pubmed: 18433921
Sousa, K. H. & Williamson, A. Symptom status and health-related quality of life: clinical relevance. Journal of advanced nursing 42, 571–577 (2003).
doi: 10.1046/j.1365-2648.2003.02660.x
Kalantar-Zadeh, K., Kopple, J. D., Block, G. & Humphreys, M. H. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. Journal of the American Society of Nephrology: JASN 12, 2797–2806 (2001).
pubmed: 11729250
Wilkins, T. & Sequoia, J. Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. American family physician 96, 170–178 (2017).
pubmed: 28762696
Hungin, A. P. S., Mitchell, C. R., Whorwell, P., Mulligan, C. & Cole, O. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. 47, 1054–1070, https://doi.org/10.1111/apt.14539 (2018).
doi: 10.1111/apt.14539
Ringel-Kulka, T. et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. Journal of clinical gastroenterology 45, 518–525, https://doi.org/10.1097/MCG.0b013e31820ca4d6 (2011).
doi: 10.1097/MCG.0b013e31820ca4d6
pubmed: 21436726
pmcid: 4372813
Rogha, M., Esfahani, M. Z. & Zargarzadeh, A. H. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterology and hepatology from bed to bench 7, 156–163 (2014).
pubmed: 25120896
pmcid: 4129566
Steenbergen, L., Sellaro, R., van Hemert, S., Bosch, J. A. & Colzato, L. S. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain, Behavior, and Immunity 48, 258–264, https://doi.org/10.1016/j.bbi.2015.04.003 (2015).
doi: 10.1016/j.bbi.2015.04.003
pubmed: 25862297
Valles-Colomer, M., Falony, G. & Darzi, Y. The neuroactive potential of the human gut microbiota in quality of life and depression, https://doi.org/10.1038/s41564-018-0337-x (2019).
doi: 10.1038/s41564-018-0337-x
Shi, H.-Y. et al. Responsiveness and Minimal Clinically Important Differences after Cholecystectomy: GIQLI Versus SF-36. Journal of Gastrointestinal Surgery 12, 1275, https://doi.org/10.1007/s11605-008-0526-7 (2008).
doi: 10.1007/s11605-008-0526-7
pubmed: 18454301
Haftenberger, M. et al. Relative validation of a food frequency questionnaire for national health and nutrition monitoring. Nutrition journal 9, 36, https://doi.org/10.1186/1475-2891-9-36 (2010).
doi: 10.1186/1475-2891-9-36
pubmed: 20840739
pmcid: 2945984
Stadlbauer, V. et al. Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis. Scientific reports 7, 15601, https://doi.org/10.1038/s41598-017-15650-9 (2017).
doi: 10.1038/s41598-017-15650-9
pubmed: 29142271
pmcid: 5688134
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C. & Knight, R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics (Oxford, England) 27, 2194–2200, https://doi.org/10.1093/bioinformatics/btr381 (2011).
doi: 10.1093/bioinformatics/btr381
Coordinators, N. R. Database resources of the National Center for Biotechnology Information. Nucleic Acids Research 44, D7–D19, https://doi.org/10.1093/nar/gkv1290 (2016).
doi: 10.1093/nar/gkv1290
Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics (Oxford, England) 26, 2460–2461, https://doi.org/10.1093/bioinformatics/btq461 (2010).
doi: 10.1093/bioinformatics/btq461
Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nature methods 7, 335–336, https://doi.org/10.1038/nmeth.f.303 (2010).
doi: 10.1038/nmeth.f.303
pubmed: 20383131
pmcid: 20383131
Zakrzewski, M. et al. Calypso: a user-friendly web-server for mining and visualizing microbiome-environment interactions. Bioinformatics (Oxford, England) 33, 782–783, https://doi.org/10.1093/bioinformatics/btw725 (2017).
doi: 10.1093/bioinformatics/btw725
Kassambara, A. ggpubr: ‘ggplot2’ Based Publication Ready Plots, https://cran.r-project.org/package=ggpubr (2018).
Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag New York, 2009).
R_Core_Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria., https://www.R-project.org/ (2017).